Analysis of intracranial tumor for drug content revealed less than 50 nM HKI-272 in intracranial DBTRG-FL tumor, more than 40-fold less than for subcutaneous tumor, and also less than the in vitro kinase assay IC50 value for this drug against EGFR. Here, EGFR is linked to neoplasm.